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Abstract. The purpose of this study is to test the feasibility of neonatal immune tolerance induction in
mice to enable long-term pharmacokinetic studies with immunogenic therapeutic monoclonal antibodies
(mAb). Neonatal immune tolerance was induced by transfer of a mAb to neonatal mice via colostrum
from nursing mother mice treated with two subcutaneous doses of a tolerogen starting within the ﬁrst
24 h after delivery. Adalimumab and efalizumab were administered as tolerogens at various dose levels.
Tolerance induction was evaluated in the offspring after reaching adulthood at 8 weeks of age. After a
single intravenous injection of the same mAb as used for tolerance induction, the pharmacokinetics of
the mAb and formation of anti-drug antibodies (ADA) in plasma were assessed using ELISA. Tolerance
induction to adalimumab was achieved in a maternal dose-dependent manner. Adalimumab immune-
tolerant offspring showed a slower adalimumab clearance (4.24±0.32 mL/day/kg) as compared to the
control group (12.09±3.81 mL/day/kg). In the control group, accelerated clearance started 7 days after
adalimumab dosing, whereas immune-tolerant offspring showed a log-linear terminal concentration-time
course. In the offspring, the absence of predose ADA levels was indicative of successful tolerance
induction. The second test compound efalizumab was not immunogenic in mice under our experimental
conditions. Overall, the present study demonstrated the suitability of neonatal immune tolerance
induction for a 4-week single dose study in adult mice with a human therapeutic mAb that is otherwise
immunogenic in laboratory animals.
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INTRODUCTION
The interest in therapeutic biologics has been growing
over the last two decades. During research and early
development of new therapeutic biologics, animal studies
are required to assess their efﬁcacy, pharmacokinetic (PK)
and pharmacodynamic (PD) properties, and safety. Since
therapeutic biologics are usually human or humanized
proteins, they can be perceived as foreign in nonclinical
species and elicit an immune response (1). The immune
response usually leads to the formation of drug-speciﬁc anti-
drug antibodies (ADA)—the measurable hallmark of immu-
nogenicity. The formation of ADA can have impact on safety,
efﬁcacy, and PK of a therapeutic protein. ADA-driven effects
on safety include hypersensitivity reactions (1,2), whereas the
efﬁcacy of the therapeutic protein can be affected in two
different ways: either by reducing or eliminating its biological
activity or by changing its PK properties and thus altering
exposure. The former effect is caused by ADA binding to the
epitopes on the therapeutic protein that are essential for
biological activity (so-called neutralizing antibodies), while all
ADA, both neutralizing and non-neutralizing, may change
clearance of the therapeutic protein. Such change in clearance
alters the exposure to the therapeutic protein and thus its
efﬁcacy. For most therapeutic proteins, including monoclonal
antibodies (mAb), ADA formation increases clearance (3–5);
for smaller therapeutic proteins, complexation with ADA can
decrease clearance (6,7).
Thus, the immune response in animals can alter the
outcome of animal studies and even prevent the conduct of
long-term animal studies. In this context, studies are consid-
ered long-term, if their duration exceeds a 7 to 10 days—period
usually needed for induction of an immune response in
laboratory animals (3,5). On the other hand, immunogenicity
of human/humanized proteins in animals is considered to be
irrelevant for predicting potential immunogenicity in humans
(8). Therefore, suppression of an immune response in animal
studies can often be beneﬁcial for the translation of animal study
results with human/humanized proteins to humans. For
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instance, due to the early onset of the immune-mediated
clearance in PK studies, often after only 7 to 10 days (3,5), the
PK of immunogenic mAbs sometimes can only be followed over
one half-life or less, which leads to uncertainty in PK parameter
estimates.
Several approaches have been described for suppres-
sion of the immune response in animal models. Cyclospor-
ine, mycophenolic acid, FK506, anti-CD4 antibodies or
combinations thereof have been used for this purpose,
particularly in studies aimed to prevent allograft rejection
in animals (9–11). For studies in mice, the use of severe
combined immunodeﬁciency (SCID) mice can be an
alternative to conduct studies without interference from
an immune response. Both approaches involve general
inhibition of the immune system, which can be disadvan-
tageous in studies requiring a fully functional immune
system. An alternative approach, which does not interfere
with the overall functionality of the immune system, is to
use human immunoglobulin G1 (IgG1) immune-tolerant
mouse. Recently, we reported the generation of human
IgG1 immune-tolerant mice expressing an Ig mini-
repertoire (12). These mice are immune-tolerant to a
broad range of IgG1 mAbs and, therefore, can be used
for long-term PK studies with several mAbs. However,
highly immunogenic mAbs, such as adalimumab, were not
tolerated by our transgenic mouse model (unpublished
data). Another alternative method is the antigen-speciﬁc
tolerance induction, which also does not interfere with the
overall functionality of the immune system. Intravenous
(IV) injection of a high dose of a soluble antigen was
shown to induce a state of long-lasting, antigen-speciﬁc
immune tolerance (high-dose immune tolerance) (13). This
approach has been successfully used to enable a safety
study with an immunogenic mAb in mice (14). However,
high-dose immune tolerance induction is not applicable for
studies in which low-single dose is used or necessary dose
levels cannot be reached. An alternative antigen-speciﬁc
approach is neonatal immune tolerance induction (15,16).
Exposure of newborns to a tolerogen may render them
immune tolerant to the tolerogen. In rodents, the exposure
of suckling pups to a tolerogenic IgG can be accomplished
via its administration to nursing mothers, with subsequent
milk excretion of the IgG and intestinal absorption in
neonates via the neonatal Fc receptor (FcRn). Although
this approach is well established in the literature, it has
obviously not yet been used for tolerance induction in
long-term studies with therapeutic biologics.
In this study, we aimed at proving the feasibility of
neonatal immune tolerance induction in mice using
adalimumab (Humira®) and efalizumab (Raptiva®) as test
compounds. Adalimumab, a human anti-tumor necrosis
factor α mAb, is highly immunogenic in laboratory animals.
Immunogenicity has been observed following single adminis-
tration to mice, minipigs, and cynomolgus monkeys (F.
Hoffmann-La Roche, unpublished data; 5,17). Efalizumab, a
humanized anti-CD11a antibody, was found immunogenic
following multiple administrations to mice (F. Hoffmann-La
Roche, unpublished data). Both compounds are not cross-
reactive in mice. Therefore, neither pharmacokinetics nor
immunogenicity is inﬂuenced by binding to the respective
target.
In the present paper, we demonstrate the feasibility of a
compound-speciﬁc neonatal immune tolerance induction for
adalimumab in mice, which allowed us to conduct a single
dose PK study over 4 weeks without impediment from an
immune response. Efalizumab failed to be immunogenic
under our experimental conditions so that tolerance induction
could not be demonstrated.
MATERIALS AND METHODS
Animals and Test Substances. Pregnant C57BL/6J inbred
mice were obtained from Janvier (Route des Chênes Secs, le
Genest St Isle, France). Adalimumab (Humira®) was obtain-
ed from commercial sources. Efalizumab (Raptiva®) was
obtained from Genentech Inc. (South San Francisco, USA).
Immune Tolerance Induction. Nursing mice (2–3 per
dose group) received two doses of either adalimumab (1, 3,
12, or 40 mg/kg) or efalizumab (12 or 160 mg/kg) via
subcutaneous injection in the interscapular area. The ﬁrst
dose was administered within 24 h after delivery, and the
second dose was given 48 h after the ﬁrst dose. Nursing mice
of the control groups received no treatment. The mice were
kept with their pups in separate cages during 22 lactating days
with free access to food and water. Thereafter, a terminal
blood sample was collected from the mothers for ADA
determination, the mothers were sacriﬁced, and the offspring
were placed in separate cages according to maternal dose and
gender.
Pharmacokinetic Studies in Offspring to Test Immune
Tolerance Induction. At about 8 weeks after birth, immune
tolerance induction was assessed by conducting a PK study in
offspring animals weighing between 18 and 25 g. Both male
and female animals were used for this study (see Table I).
The offspring received a single intravenous dose of either
adalimumab (5 mg/kg) or efalizumab (2 mg/kg) injected into
the tail vein (n=5–8/dose group; Table I).
Serial samples of blood (20 μl) were collected from each
animal at 30 min before the injection and 5 min, 7, 24, 48, 72,
168 h and then weekly for up to 4 weeks after the injection.
Blood was collected from the tail vein using K3-EDTA
microcapillaries (Minivette®, Sarstedt AG&Co, Nümbrecht,
Germany). Plasma was separated by centrifugation, and
samples were stored at −20°C until analysis. All animal
experiments were conducted according to applicable guide-
lines and approved by Swiss authority. The animal laboratory
is AAALAC accredited.
Total mAb Assay. Total mAb concentrations were mea-
sured with a generic enzyme-linked immunosorbent assay
(ELISA) (18). The assay was performed in streptavidin-
coated 96 well microplates using biotinylated and
digoxigenylated mouse monoclonal anti-human Fcγ antibod-
ies as capture and detection reagents. Quality control (QC)
samples, calibration standards, and study samples were
analyzed at a constant plasma concentration of 5% and the
working range of the assay was between 0.006 and 0.4 μg/mL.
A 4 parameter logistic function was ﬁtted to the calibration
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standard data; QC and study sample concentrations were
determined by interpolation.
Generic Anti-drug Antibody Assay. Anti-drug antibodies
(ADA) were analyzed with a generic ADA assay in
streptavidin-coated 96 well microplates as described by
Stubenrauch et al. (19). In this sandwich-ELISA, ADAs are
converted to immune complexes by pre-incubation with
excess drug. A biotinylated mouse anti-human Fab constant
domain Fab was used as capture reagent. Detection of bound
immune complexes was accomplished with a peroxidase-
labeled rabbit anti-murine Fc antibody. A conjugate
consisting of human Fab and murine IgG was used as positive
control and for calibration. The assay was conducted in 2%
mouse plasma. The cut point was deﬁned as the lower limit of
quantiﬁcation and corresponded to a concentration of
0.125 μg/mL of the positive control (calibration range 0.125–
1.875 μg/mL). A 4 parameter logistic function was ﬁtted to
the calibration standard data, QC, and study sample concen-
trations were determined by interpolation. Quantitative
results for study samples are based on the used positive
control and are given in μg-equivalent/mL.
Pharmacokinetic Evaluation. PK parameters were esti-
mated by standard non-compartmental analysis using the
pharmacokinetic evaluation program Phoenix WinNonlin 6.2
(Pharsight, USA). Individual plasma concentration-time pro-
ﬁles were used for parameter estimation. The maximum
plasma drug concentration (Cmax) was determined directly
from the plasma concentration-time proﬁles. The area under
the concentration-time curve from zero to the last measurable
concentration (AUClast) was calculated by linear trapezoidal
rule. The AUC from time zero to inﬁnity (AUCinf) was
calculated from AUClast with extrapolation of the terminal
portion of the concentration-time curve from the last
measurable concentration to inﬁnity using the apparent
terminal elimination rate (λz). λz was obtained by log-linear
regression of the terminal phase of the plasma concentration-
time curve (time period for assessment: 72–672 h for
animals without apparent accelerated decline, 336 h to the
last measurable time point for animals with apparent
accelerated decline). Clearance (CL) was calculated as
dose/AUCinf. The apparent terminal half-life (T1/2) was
derived as T1/2=ln2 / λz.
Statistical Analysis. Statistical analysis of the PK param-
eters CL and T1/2 was performed using GraphPad Prism
Version 6.0 (GraphPad Software Inc., La Jolla, USA) by one-
way ANOVA followed by Dunnett’s multiple comparison
test. Predose ADA levels were correlated with AUC values
by Spearman rank correlation.
RESULTS
Treatment of Dams
Two subcutaneous doses of 1, 3, 12, or 40 mg/kg
adalimumab or 12 or 160 mg/kg efalizumab were well
tolerated in the mother mice. The litter size ranged between
4 and 9, and most offspring grew normally in all treatment
groups. Terminal samples from all mothers treated with
adalimumab were tested positive (>1.875 μg-equivalent/mL)
for ADA (mother mice treated with efalizumab were not
tested for ADA).
Pharmacokinetics of Adalimumab in Offspring
The mean plasma concentration-time curves of
adalimumab (5 mg/kg) in the offspring of adalimumab-
treated mothers differed markedly from that of the control
group (Fig. 1). In the control group, an accelerated decline of
the plasma concentration started on day 7 after administra-
tion, whereas such acceleration was not apparent in the 1 and
3 mg/kg groups until day 14. We observed no accelerated
decline in the 12 mg/kg group, in which adalimumab plasma
concentration declined in a log-linear fashion until the end of
the study. In the 40 mg/kg group, three (50%) mice showed
no indication of the accelerated decline, while in three other
mice the accelerated decline started after day 7 or day 21
(data not shown).
The PK proﬁles of adalimumab were in line with the
terminal ADA concentration in the offspring. The ADA
Table I. Overview on Mouse In Vivo Studies
Tolerance induction in lactating mice PK study in offspring
mAb tolerogen Dose (mg/kg)a Offspring (males/females) / mother mice mAb for PK Dose (mg/kg)
Adalimumab –b 8(8M/0F) / 3 Adalimumab 5
1 8(8M/0F) / 3 Adalimumab 5
3 8(8M/0F) / 3 Adalimumab 5
12 6(3M/3F) / 2 Adalimumab 5
40 6(3M/3F) / 2 Adalimumab 5
Efalizumab –b 5(3M/2F) / 1 Efalizumab 2
12 6(2M/4F) / 2 Efalizumab 2
160 6(3M/3F) / 2 Efalizumab 2
160 6(1M/5F) / 2 Adalimumabc 5
F female, M male, mAb monoclonal antibody, PK pharmacokinetics
aTwo subcutaneous administrations (within 24 h after delivery and 48 h after the ﬁrst dose)
bControl
cCompound speciﬁcity control
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concentration was the highest in the control group (range 83.4
to 184; mean 121 μg-equivalent/mL) followed by the 1 mg/kg
group (mean 69.7 μg-equivalent/mL) and the 3 mg/kg group
(mean 42.7 μg-equivalent/mL). All mice from the 12 mg/kg
group were tested negative for ADA. In the 40 mg/kg group,
only those mice that showed log-linear terminal PK proﬁle
had no detectable ADA, whereas all mice having the
accelerated decline were ADA-positive (range 0.79 to
8.08 μg-equivalent/mL).
Pharmacokinetic parameters for adalimumab differed
between the groups (Table II and Fig. 2). Mean clearance
decreased and mean apparent terminal half-life increased
with increasing maternal dose of adalimumab, with the
12 mg/kg group showing minimal clearance and maximal
half-life; the differences from the control group were signif-
icant in the 12 and 40 mg/kg groups. The marked interindi-
vidual variability in the 40 mg/kg group was also evident for
PK parameters: the three ADA-negative mice from this
group showed clearance similar to that of the 12 mg/kg group
(range 3.35 to 4.04 mL/day/kg), whereas clearance in the
other, ADA-positive, mice was between 5.49 and 14.5 mL/
day/kg (see also Fig. 2). In some dose groups, both male and
female animals were used (Table I); since we did not observe
any obvious sex differences in PK, data from these animals
were pooled.
To evaluate possible correlation with PK results, we
determined ADA levels before adalimumab administration in
the offspring. The predose ADA levels in the offspring were
inversely correlated with the AUClast (Fig. 3). Detectable
predose ADA levels were observed in all offspring that were
tested positive in the terminal ADA samples, i.e., in all
offspring from the 1 and 3 mg/kg groups (mean 1.39 and
0.967 μg-equivalent/mL, respectively) as well as in the three
ADA-positive mice in the 40 mg/kg group (Fig. 4). Of these
three mice, one showed a relatively low predose ADA level
(0.422 μg-equivalent/mL), whereas one animal had the
highest predose ADA level among all tested animals
(5.012 μg-equivalent/mL).
Pharmacokinetics of Efalizumab in Offspring
The mean plasma concentration-time curves of
efalizumab (2 mg/kg) in the offspring from the control and
efalizumab-treated mothers were all similar with a log-linear
elimination phase and no indication of accelerated clearance
(Fig. 5). We found no marked differences in clearance, with
mean (±standard deviation) clearance being 4.44±0.58 (con-
trol), 4.37±0.50 (12 mg/kg group), and 3.31±0.47 mL/day/kg
(160 mg/kg group).
In agreement with the PK data, predose as well as
terminal study samples of all offspring from efalizumab-
treated mothers were tested negative for ADA.
Compound Specificity of Immune Tolerance Induction
To test the speciﬁcity of immune tolerance induction, we
administered adalimumab to the offspring of efalizumab-treated
(160 mg/kg) mothers (Fig. 5). Similar to the adalimumab control
group, the adalimumab plasma concentration-time curve in
these offspring showed an accelerated decline starting 7 days
after administration. Accordingly, mean clearance in this group
was close to that of the adalimumab controls (9.12±2.81 vs. 12.1
±3.81 mL/day/kg).
ADA data for these offspring were consistent with the
PK data and demonstrated that neonatal exposure to
efalizumab did not confer immune tolerance to adalimumab:
While predose samples were tested negative for ADAs,
terminal samples were ADA positive in all 6 animals
(>1.88 μg-equivalent/mL).
Fig. 1. Mean plasma concentration-time curves of adalimumab
following intravenous administration of 5 mg/kg to the offspring from
mother mice treated with two subcutaneous doses of 0 (control), 1, 3,
12, and 40 mg/kg adalimumab administered after delivery (mean±SD,
n=6–8/group)
Table II. Pharmacokinetic Parameters of Adalimumab Following Single IVAdministration to Offspring after Immune Tolerance Induction
PK parameter
Adalimumab dose in lactating mice (mg/kg)a
–b 1 3 12 40
CL (mL/day/kg) 12.1±3.81 10.3±2.60 8.77±2.67 4.24±0.31* 7.20±4.87*
Vss (mL/kg) 52.0±12.8 66.3±10.6 60.8±9.90 85.0±10.8 77.1±11.5
T1/2 (day) 2.20±1.07 3.05±1.03 4.16±1.62 14.8±2.56* 10.3±8.16*
AUClast (μg⋅day/mL) 449±137 510±126 601±153 887±62.0 734±282
AUCinf (μg⋅day/mL) 449±136 512±126 609±154 1190±80.2 963±493
Data presented as means±standard deviation
AUClast area under the concentration-time curve from zero to the last measurable concentration, AUCinf area under the concentration-time
curve extrapolated to inﬁnity, CL clearance, T1/2 terminal half-life, Vss volume of distribution in steady state
aTwo subcutaneous administrations (within 24 h after delivery and 48 h after the ﬁrst dose)
bControl
*p<0.05, statistically signiﬁcant difference from control
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DISCUSSION
Exposing neonatal mice to an immunogenic mAb
resulted in immune-tolerant adult mice and allowed a
successful PK assessment of an immunogenic biologic without
interference from immune-related accelerated clearance. We
accomplished neonatal exposure by administration of a mAb
to nursing mothers after delivery. Immunoglobulins like mAb
are excreted in milk and absorbed from the intestine of
suckling pups via the neonatal Fc receptor (FcRn) in several
species including mice (20). Therefore, such delivery mode to
neonates is only applicable to IgG and Fc-fusion proteins
capable of FcRn binding. The chosen approach allows
neonatal tolerogen exposure of newborn mice without direct
tolerogen administration, thereby reducing the burden on the
newborn animals.
After delivery, mother mice received two subcutaneous
doses (48 h apart) of respective tolerogen. This dosing
schedule was similar to that described by Halsey et al. and
was not further optimized (15). We did not assess the
exposure of lactating mice to adalimumab and efalizumab in
the present study to reduce experimental burden on the mice.
However, since both mAbs are well absorbed after subcuta-
neous administration in other species (SC bioavailability in
humans: 64 and 56%, respectively) (21,22), the systemic
exposure of nursing mice with subsequent mAb transfer to
pups can be assumed. Moreover, the formation of ADA in
several dose groups provides indirect evidence for successful
mAb transfer to pups (see also below).
Adalimumab-treated mother mice developed ADA
against adalimumab. Since endogenous mouse IgG is also
transferred to suckling pups (20), the pups were probably also
exposed to maternal ADA. It is, however, unclear, whether
pups were also exposed to adalimumab-ADA immune
complexes, which could have contributed to tolerance induc-
tion in addition to the free adalimumab. Notably, IgG
immune complexes containing ovalbumin as antigen and
transferred to mouse pups via milk have been shown to be
more efﬁcient than milk-born free antigen in inducing oral
tolerance and preventing asthma (23). Ovalbumin-IgG im-
mune complexes formed under excess of IgG have been
shown to be excreted in mice via milk and to reach systemic
circulation in nursed neonates (24). Bispeciﬁc antigens like
adalimumab, however, may also form large, cross-linked
immune complexes. It remains open whether such cross-
Fig. 2. Individual and mean clearance values of adalimumab after
intravenous administration of 5 mg/kg to the offspring from mother
mice treated with two subcutaneous doses of 0 (control), 1, 3, 12, and
40 mg/kg adalimumab administered after delivery
Fig. 3. Inverse relationship between individual predose anti-
adalimumab antibody levels and area under the plasma
concentration-time curve of adalimumab after intravenous adminis-
tration of 5 mg/kg to the offspring from mother mice treated with two
subcutaneous doses of 1, 3, 12, or 40 mg/kg adalimumab administered
after delivery. The data suggest that predose anti-adalimumab
antibody levels are predictive for degree of immune tolerance
(Spearman Rank Correlation r=−0.835; P<0.0001)
Fig. 4. Predose anti-adalimumab antibody levels in the offspring in
relation to the maternal adalimumab dose: individual and mean
predose anti-adalimumab antibody levels in the offspring from
mother mice treated with two subcutaneous doses of 1, 3, 12, or
40 mg/kg adalimumab administered after delivery
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linked immune complexes are transferred to the nursed
neonate via the FcRn pathway, as cross-linked immune
complexes have been reported to undergo lysosomal break-
down rather than FcRn-mediated recycling/transcytosis (25).
The study results demonstrate tolerance induction for
adalimumab in a maternal dose-dependent manner. On the
basis of available data, it remains unclear whether there is a
dose-dependent threshold for immune tolerance or a contin-
uous dose-effect. Full immune tolerance was achieved at a
maternal dose level of 12 mg/kg. At a maternal dose level of
40 mg/kg, however, tolerance induction failed in some
offspring. Nevertheless, a bell-shaped relationship between
maternal dose and tolerance induction appears to be unlikely,
as the offspring mice without tolerance induction were all
from the same mother mouse. Even among the offspring from
this mother, one animal showed relatively low predose ADA
levels, while another showed the highest predose ADA level
among all animals. The reason for this unexpected ﬁnding is
unknown. It is worth mentioning, however, that Komatsu
et al. found no indication for a bell-shaped relationship
between maternal IgG tolerogen dose and tolerance induc-
tion in mice (16).
The tolerogen dose required for tolerance induction may
depend on mouse strain as well as on tolerogen. Komatsu and
co-workers demonstrated that lower IgG doses are required
for immune tolerance induction in C57BL/6 mice as com-
pared to BALB/c mice (16). In their study, low single
intravenous doses of human IgG in mothers, 0.5 μg in
C57BL/6 and 50 μg in BALB/c mice (equivalent to ca. 0.025
and 2.5 mg/kg), were sufﬁcient to induce tolerance in the
offspring.
The PK study with adalimumab in the immune tolerant
group enabled us to perform an accurate PK assessment in
the absence of accelerated immune-mediated clearance. In
the 12 mg/kg group, adalimumab exhibited a very low
clearance (4.24 mL/day/kg), resulting in a long half-life of
14.8 days. This clearance was at the lower end of the reported
range for therapeutic mAb clearance in mice of ∼3–16 mL/
day/kg (26). In the PK assessment of immunogenic
biotherapeutics in non-tolerant laboratory animals, the phase
of immune-mediated accelerated clearance is usually
disregarded and the terminal phase is deﬁned from
concentration-time points that precede the onset of the
accelerated clearance (3). Such PK assessment for
adalimumab in the control group yielded markedly higher
clearance values due to an inappropriate assessment of the
terminal elimination phase as a consequence of short
observation time of 7 days and, thus, a misleading PK
evaluation for adalimumab (data not shown). Importantly,
the phase of accelerated clearance was not disregarded in the
PK evaluation in the present study (see BMATERIALS AND
METHODS^) in order to better demonstrate PK differences
across the dose groups.
In this study, we could demonstrate the beneﬁcial effects
of immune-tolerant test animals only for PK assessment for
adalimumab. The second test compound, efalizumab, was
non-immunogenic under our test conditions, and hence, we
were not able to study tolerance induction to efalizumab.
Dosing of adalimumab to the offspring from efalizumab-
treated mothers conﬁrmed the expected compound speciﬁcity
of tolerance induction. The constant IgG sequences of
adalimumab and efalizumab are very similar, differing only
in two sites in the CH3 domain (EU site D356 vs E356 and
L358 vs M358) (for sequences see http://www.drugbank.ca/
drugs/DB00051 for adalimumab and http://www.drugbank.ca/
drugs/DB00095 für efalizumab). Our experimental results
suggest that the immunogenic epitope(s) of adalimumab are
located in those sequences, where both molecules differ, i.e.,
either in variable regions or in the CH3 domain.
The microsampling technique (20 μL blood volume per
sample) allowed serial blood sampling in an individual animal
for analysis of both mAb and ADA levels. This approach
helped us to assess and correlate PK results and ADA data
for individual animals. A relevant fraction of the offspring
from adalimumab-treated mothers was positive for ADA
prior to adalimumab dosing and the level of predose ADAs
correlated with the PK of adalimumab in the offspring. It
would be interesting to understand whether the predose
ADA in offspring are due to maternal transfer of ADA to
offspring or whether they reﬂect an immune response against
adalimumab in the offspring following exposure via milk.
Although serial sampling starting at weaning would have
addressed this question, we avoided any sampling on the
offspring prior to adalimumab administration for experimen-
tal reasons. Circumstantial evidence, however, indicates that
the predose ADA were formed in the offspring themselves:
All adalimumab-treated maternal mice showed relevant
ADA levels at weaning, whereas the predose ADA preva-
lence in offspring depended on the maternal adalimumab
dose (offspring of mothers treated with 12 mg/kg had no
predose ADA and offspring of mothers treated with 1 or
3 mg/kg showed marked ADA levels). The lack of predose
ADA in the 12 mg/kg group suggests that the predose ADA
in the offspring of other groups is formed in the offspring
animals themselves. Of note, animals with no detectable
ADA levels at predose also had ADA-negative terminal
samples. Thus, predose ADA levels may allow pre-
Fig. 5. Lack of immunogenicity of efalizumab and speciﬁcity of the
immune tolerance induction: Mean plasma concentration-time curves
of efalizumab after intravenous administration of 2 mg/kg to the
offspring from mother mice treated with two subcutaneous doses of 0
(control), 12, and 160 mg/kg efalizumab administered after delivery,
as well as mean plasma concentration-time curve of adalimumab after
intravenous administration of 5 mg/kg adalimumab to the offspring
from mother mice treated with two subcutaneous doses of 160 mg/kg
efalizumab administered after delivery (mean±SD, n=5–8/group)
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experimental assessment of the tolerance induction, lending
themselves for a triage of test animals for successful tolerance
induction prior to initiation of studies.
In the present study, we demonstrated successful use
of neonatal immune tolerance induction to enable a PK
study with a highly immunogenic mAb in mice. Although
neonatal immune tolerance induction is well known in the
literature, we are not aware of any reports on its use in
the development of therapeutic mAbs. Neonatal immune
tolerance induction has been described for rodents and
rabbits following neonatal exposure to a protein
(15,16,27). Such studies following administration of a
protein to neonates are apparently missing in non-human
primates. In both non-human primates and dogs, however,
neonatal immune tolerance induction was successfully
used to facilitate gene therapy (28). Gene therapy in
neonates of both species rendered them immune tolerant
to the nonself protein formed from gene therapy.
Neonatal immune tolerance induction is of particular
interest for studies with immunogenic proteins in mice. In
mice, it takes only about 8 weeks for a newborn to reach the
young adult stage, in which it can be used for subsequent
studies. Such time frame is usually compatible with time
frames of experimental planning in drug development,
making the neonatal immune tolerance induction an attrac-
tive alternative to other approaches for tolerance induction in
mice. Due to its antigen speciﬁcity, neonatal immune
tolerance induction is particularly attractive for the studies
that require otherwise a fully functional immune system.
Overall, the present study demonstrated the suitability of
neonatal immune tolerance induction for a 4-week single
dose study in 8-week-old mice with a human mAb that is
otherwise very immunogenic in laboratory animals. Further
work will be required to explore the suitability of this
approach for longer studies including multiple dose studies.
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